Bard1 Life Sciences Limited (BD1:ASX)

Company Overview

BARD1 Life Sciences Limited is an Australia-based medical diagnostics company. The Company is engaged in research, development, and commercialization of non-invasive diagnostic products for the early detection of cancer. The Company’s technologies include BARD1, SubB2, NET and hTERT. BARD1 is a biomarker platform covering various tumor markers including nucleic acids, proteins, and autoantibodies for early cancer diagnosis.SubB2M is a pan-cancer probe for monitoring cancer treatment response and recurrence across a wide range of cancers. NET is designed to capture and purify biomarkers, including acids, cells, and exosomes. hTERT is an antibody-based assay to detect hTERT, a component of telomerase, in cells.